1108 related articles for article (PubMed ID: 15713482)
1. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
2. Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.
Rohrbach F; Gerstmayer B; Biburger M; Wels W
Clin Cancer Res; 2000 Nov; 6(11):4314-22. PubMed ID: 11106249
[TBL] [Abstract][Full Text] [Related]
3. Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene.
Gerstmayer B; Altenschmidt U; Hoffmann M; Wels W
J Immunol; 1997 May; 158(10):4584-90. PubMed ID: 9144470
[TBL] [Abstract][Full Text] [Related]
4. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway.
Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E
Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794
[TBL] [Abstract][Full Text] [Related]
5. Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein.
Gerstmayer B; Hoffmann M; Altenschmidt U; Wels W
Cancer Immunol Immunother; 1997; 45(3-4):156-8. PubMed ID: 9435862
[TBL] [Abstract][Full Text] [Related]
6. Monovalent antibody scFv fragments selected to modulate T-cell activation by inhibition of CD86-CD28 interaction.
Kolly R; Thiel MA; Herrmann T; Plückthun A
Protein Eng Des Sel; 2007 Feb; 20(2):91-8. PubMed ID: 17289805
[TBL] [Abstract][Full Text] [Related]
7. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
8. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
[TBL] [Abstract][Full Text] [Related]
9. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity.
Liao KW; Chen BM; Liu TB; Tzou SC; Lin YM; Lin KF; Su CI; Roffler SR
Cancer Gene Ther; 2003 Oct; 10(10):779-90. PubMed ID: 14502231
[TBL] [Abstract][Full Text] [Related]
10. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein.
Blanco B; Holliger P; Alvarez-Vallina L
Cancer Gene Ther; 2002 Mar; 9(3):275-81. PubMed ID: 11896444
[TBL] [Abstract][Full Text] [Related]
11. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
[TBL] [Abstract][Full Text] [Related]
12. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains.
van den Beucken T; van Neer N; Sablon E; Desmet J; Celis L; Hoogenboom HR; Hufton SE
J Mol Biol; 2001 Jul; 310(3):591-601. PubMed ID: 11439026
[TBL] [Abstract][Full Text] [Related]
13. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL.
Lanier LL; O'Fallon S; Somoza C; Phillips JH; Linsley PS; Okumura K; Ito D; Azuma M
J Immunol; 1995 Jan; 154(1):97-105. PubMed ID: 7527824
[TBL] [Abstract][Full Text] [Related]
14. Comparison of CD28-B7.1 and B7.2 functional interaction in resting human T cells: phosphatidylinositol 3-kinase association to CD28 and cytokine production.
Ghiotto-Ragueneau M; Battifora M; Truneh A; Waterfield MD; Olive D
Eur J Immunol; 1996 Jan; 26(1):34-41. PubMed ID: 8566081
[TBL] [Abstract][Full Text] [Related]
15. A new model of trispecific antibody resulting the cytotoxicity directed against tumor cells.
Song LP; Cheng JL; Wang XB; Zhang Z; Fang M; Zhou ZY; Huang HL
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Jun; 35(6):503-10. PubMed ID: 12796809
[TBL] [Abstract][Full Text] [Related]
16. Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4.
Höllsberg P; Scholz C; Anderson DE; Greenfield EA; Kuchroo VK; Freeman GJ; Hafler DA
J Immunol; 1997 Nov; 159(10):4799-805. PubMed ID: 9366404
[TBL] [Abstract][Full Text] [Related]
17. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
Müller D; Frey K; Kontermann RE
J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748
[TBL] [Abstract][Full Text] [Related]
18. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
19. Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II.
Lando PA; Olsson C; Kalland T; Newton D; Kotb M; Dohlsten M
J Immunol; 1996 Oct; 157(7):2857-63. PubMed ID: 8816390
[TBL] [Abstract][Full Text] [Related]
20. B7-1-HSA (CD80-CD24), a recombinant hybrid costimulatory molecule retains ligand binding and costimulatory functions.
Wang YC; Sashidharamurthy R; Nagarajan S; Selvaraj P
Immunol Lett; 2006 Jun; 105(2):185-92. PubMed ID: 16621031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]